What is William Blair’s Estimate for MaxCyte Q1 Earnings?

MaxCyte, Inc. (NASDAQ:MXCT) – Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for MaxCyte in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst M. Larew anticipates that the company will earn ($0.09) per share for the quarter. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.30) EPS.

Several other research analysts have also weighed in on MXCT. BTIG Research set a $6.00 price objective on MaxCyte and gave the stock a “buy” rating in a research report on Wednesday. Stifel Nicolaus cut their target price on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday.

MaxCyte Price Performance

MXCT stock opened at $3.06 on Thursday. The firm has a market capitalization of $324.23 million, a PE ratio of -9.00 and a beta of 1.35. MaxCyte has a 1 year low of $2.76 and a 1 year high of $5.26. The business has a 50 day simple moving average of $4.19 and a 200-day simple moving average of $3.98.

Institutional Investors Weigh In On MaxCyte

A number of hedge funds and other institutional investors have recently modified their holdings of MXCT. Franklin Resources Inc. acquired a new position in shares of MaxCyte during the 3rd quarter worth approximately $260,000. Barclays PLC increased its position in shares of MaxCyte by 329.3% in the third quarter. Barclays PLC now owns 165,765 shares of the company’s stock worth $645,000 after acquiring an additional 127,156 shares in the last quarter. Geode Capital Management LLC grew its holdings in MaxCyte by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock valued at $9,628,000 after purchasing an additional 47,960 shares in the last quarter. Mudita Advisors LLP grew its holdings in MaxCyte by 5.6% during the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock valued at $12,267,000 after purchasing an additional 167,101 shares in the last quarter. Finally, State Street Corp boosted its stake in MaxCyte by 5.1% during the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company’s stock valued at $8,827,000 after acquiring an additional 111,066 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.